

Subject: IDT's Self Attestation to Biosecurity and Compliance with Nucleic Acid Synthesis Screening Framework

Dear Valued Customers,

As a founding member of the International Gene Synthesis Consortium (IGSC), Integrated DNA Technologies (IDT) has demonstrated a steadfast commitment to biosecurity for over a decade.

Compliance with New Guidelines

In response to President Biden's 2023 Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence, IDT is committed to meeting the new guidelines outlined in the OSTP's Framework for Nucleic Acid Synthesis Screening by October 2024. These guidelines include:

- 1. Screening purchase orders of synthetic nucleic acids to identify sequences of concern (SOCs).
- 2. Screening customers of purchase orders of synthetic nucleic acids with SOCs to verify legitimacy.
- 3. Reporting potentially illegitimate purchase orders of synthetic nucleic acids involving SOCs to the relevant authorities.
- 4. Retaining records relating to orders for synthetic nucleic acids.
- 5. Taking steps to ensure cybersecurity and information security.

Should any relevant information change, IDT agrees to update this statement and notify customers immediately.

We remain dedicated to ensuring the highest standards of biosecurity and compliance, and we are ready to meet these new challenges head-on.

Best regards,

Ross Allen

General Counsel

Integrated DNA Technologies (IDT)

GLOBAL HEADQUARTERS

Integrated DNA Technologies, Inc. 1710 Commercial Park Coralville, Iowa 52241 USA